Abstract
Management of head and neck hemangiomas with oral propranolol versus oral itraconazole in conjugation with injection sodium tetra decyl sulphate. This prospective parallel clinical trial was done to check for the effectiveness of oral propranolol and oral itraconazole when used in conjugation with inj. sodium tetra decyl sulphate in treatment of head and neck haemangiomas in adult patients visiting department of ENT and head and neck surgery, VIMSAR, Burla. All the patients visiting the department with hemangioma (diagnosed clinically and by FNAC) were considered and only those who gave written informed consent and were according to our inclusion and exclusion criteria were included into the study as subjects. Dimension (length, width and hemi-circumference) of the haemangiomas were measured using disposable paper taper measures. Depth of the hemangioma was calculated based on formula and using that volume was calculated both at baseline and after 8 weeks of drug administration. Data so collected was entered into Microsoft Office Excel 2013 and statistical analysis was performed using SPSS Version 20.0. Descriptive statistics was calculated and student’s t test (paired and unpaired) was used to compare within the group (before and after) and between the groups respectively. Statistical significance was set at p ≤ 0.05. Both the groups showed statistically significant volume reduction in the lesions [p < 0.018 (propranolo + sodium tetra decyl sulphate), p < 0.025 (itraconazole + sodium tetra decyl sulphate)]. The mean decrease in volume in propranolol group was 91.92% and that in itraconazole group was 88.97%. There was no statistical difference between the final outcome of both the groups (p < 0.766) but 3 patients on propranolol had complete resolution while 1 patient on itraconazole had complete resolution of the lesion. Oral propranolol and itraconazole are both effective and safe in hemangioma in adults. The combination with inj. sodium tetra decyl sulphate has a (1) favorable impact on decreasing the overall duration of treatment. (2) Aiding in complete resolution of lesions (especially < 3 cm). Propranolol has an edge over itraconazole (more no of tumors had complete resolution).
Similar content being viewed by others
References
Kilcline C, Frieden IJ (2008) Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 25:168
Blei F, Walter J, Orlow SJ, Marchuk DA (1998) Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 134:718
Buckmiller LM, Richter GT, Suen JY (2010) Diagnosis and management of hemangiomas and vascular malformations of the head and neck. Oral Dis 16:405–418
Berk DR, Berk EJ, Bruckner AL (2011) A novel method for calculating the volume of hemangiomas. Pediatr Dermatol 28(4):478–482
Ho NT, Lansang P, Pope E (2007) Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 56:63–68
Pope E, Krafchik BR, Macarthur C et al (2007) Oral versus highdose pulse corticosteroids for problematic infantile hemangiomas:a randomized, controlled trial. Pediatrics 119:e1239–e1247
Sans V, Dumas de la Roque E, Berge J et al (2009) Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 124:423–431
Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60(5):438–445. https://doi.org/10.1016/j.phrs.2009.05.005
Zhang D, Ma Q, Shen S et al (2009) Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction. Pancreas 38:94–100
Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163:269–274. https://doi.org/10.1111/j.1365-2133.2010.09848.x
Aletaha M, Salour H, Bagheri A, Raffati ND, Amouhashemi N (2012) Oral propranolol for treatment of pediatric capillary hemangiomas. J Ophthalmic Vis Res 7(2):130–133
Gajbhiye V, Nath S, Chatterjee S, De A, Ghosh D, Das SK (2011) Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg 16(4):173–174
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358(24):2649–2651
Fette A (2013) Propranolol in use for treatment of complex infant hemangiomas: literature review regarding current guidelines for pre assessment and standards of care before initiation of therapy. Sci World J 2013:850193. https://doi.org/10.1155/2013/850193
Painter SL et al (2016) Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol 61(1):51–58
Ohnishi K, Tagami M, Morii E, Azumi A (2014) Topical treatment for orbital capillary hemangioma in an adult using a β-blocker solution. Case Rep Ophthalmol 5:60–65
Murthy GJ, Goswami M (2012) Management of adult onset orbital hemangioma by oral propranolol: a case report. Orbit 31(5):373–375
Khoury TR (2015) Adult hepatic hemangioma: an updated review with focus on the natural course and treatment options. Abdomen 2:e908. https://doi.org/10.14800/abdomen.908
Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J et al (2010) Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 157:340–342
Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J (2011) Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol 28:649–654. https://doi.org/10.1111/j.1525-1470.2011.01551.x
Abarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS (2014) Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Am Acad Dermatol 70(6):1045–1049
Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon α2a therapy for the life—threatening haemangioma ofinfancy. N Engl J Med 326(22):1456–1463
Bauman NM, Burke DK, Smith RH (1997) Treatment of massive or life-threatening hemangiomas with recombinant α2a-interferon. Otolaryngol Head Neck Surg 117(1):99–110
Perez J, Pardo J, Gomez C (2002) Vincristine—an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol 41(2):197–199
Pope E, Krafchik BR, Macarthur C et al (2007) Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics 119(6):e1239–e1247
Grant SM et al (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 37(3):310–344
Head SA, Shi W, Zhao L, Gorshkov K, Pasunooti K, Chen Y, Deng Z, Li RJ, Shim JS, Tan W, Hartung T (2015) Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci 112(52):E7276–E7285. https://doi.org/10.1073/pnas.1512867112
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA (2010) Itraconazole, a commonly used anti-fungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17(4):388–399. https://doi.org/10.1016/j.ccr.2010.02.027
Dang Y, Ren YR, Liu JO (2010) Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci 107(10):4764–4769. https://doi.org/10.1073/pnas.0910872107
Nacev BA et al (2011) The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem 286(51):44045–44056
Goktas S et al (2014) Antiangiogenic effect of itraconazole on corneal neovascularization: a pilot experimental investigation. Ophthalmic Res 52(4):170–174
Ran Y, Chen S, Dai Y, Kang D, Lama J, Ran X, Zhuang K (2015) Successful treatment of oral itraconazole for infantile hemangiomas: a case series. J Dermatology 42(2):202–206. https://doi.org/10.1111/1346-8138.12724
Agarwal S (2012) Treatment of oral hemangioma with 3% sodium tetradecyl sulfate: study of 20 cases. Indian J Otolaryngol Head Neck Surg 64(3):205–207. https://doi.org/10.1007/s12070-011-0249-z
Choi B-E, Kim Y, Leem D-H, Baek J-A, Ko SO (2016) Utility of sodium tetradecyl sulfate sclerotherapy from benign oral vascular lesion. Maxillofac Plast Reconstr Surg 38(1):44. https://doi.org/10.1186/s40902-016-0094-9
Reddy GSP, Reddy GV, Reddy KSK, Priyadarshini BS, Sree PK (2016) Intralesional sclerotherapy: a novel approach for the treatment of intraoral haemangiomas. J Clin Diagn Res JCDR 10(1):ZD13–ZD14. https://doi.org/10.7860/jcdr/2016/17568.7137
Grover C, Khurana A, Bhattacharya SN (2012) Sclerotherapy for the treatment of infantile hemangiomas. J Cutan Aesthet Surg 5(3):201–203. https://doi.org/10.4103/0974-2077.101383
Grover C, Arora P, Kedar A, Pal P, Lal B (2010) Combination of oral corticosteroids and polidocanol sclerotherapy in the management of infantile hemangiomas. Dermatol Surg 36(12):2030–2036. https://doi.org/10.1111/j.1524-4725.2010.01760.x
Ma X, Chang M, Ouyang T et al (2015) Combination of propranolol and sclerotherapy for treatment of infantile parotid hemangiomas. Int J Clin Exp Med 8(7):10865–10874
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081601/figure/F1/
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Ethical approval
The study did not require any ethical approval of any kind.
Informed consent
The participants did not have to provide formal consent for the treatment.
Rights and permissions
About this article
Cite this article
Panditray, S., Acharya, S., Prusty, N. et al. Management of Head and Neck Hemangiomas in Adults: Oral Propranolol Versus Oral Itraconazole in Conjugation with Injection Sodium Tetra Decyl Sulphate. Indian J Otolaryngol Head Neck Surg 71 (Suppl 1), 566–573 (2019). https://doi.org/10.1007/s12070-018-1410-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12070-018-1410-8